Moleculin Biotech Inc reports results for the quarter ended September 30 - Earnings Summary

Moleculin Biotech

13/11/2026 22:46

Moleculin Biotech Inc MBRX.OQ reported a quarterly adjusted loss of $9.59​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $-340.00.  The mean expectation of three analysts for the quarter was for a loss of $8.87 per share. Wall Street expected results to range from $-10.80 to $-6.80 per share.
Reported revenue was zero​; analysts expected zero. 
Moleculin Biotech Inc's reported EPS for the quarter was a loss of $9.59​.
The company reported a quarterly loss of $7.27 million.
Moleculin Biotech Inc shares had fallen by 19.5% this quarter and lost 87.8% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 33.2% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Moleculin Biotech Inc is $60.00, about 86.6% above its last closing price of $8.06
This summary was machine generated from LSEG data November 13 at 10:46 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Sep. 30 2026 
-8.87
-9.59
Missed
Jun. 30 2026 
-31.07
-28.00
Beat
Mar. 31 2026 
-33.27
-70.80
Missed
Dec. 31 2025 
-1.22 hundred
2.61 hundred
Beat